BLUENERGIES LTD (BLU.CA) Stock Price, Forecast & Analysis

TSX:BLU • CA0959221007

1.54 CAD
-0.01 (-0.65%)
Last: Feb 17, 2026, 07:00 PM

BLU.CA Key Statistics, Chart & Performance

Key Statistics
Market Cap195.27M
Revenue(TTM)N/A
Net Income(TTM)N/A
Shares126.80M
Float104.23M
52 Week HighN/A
52 Week LowN/A
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)N/A
PEN/A
Fwd PEN/A
Earnings (Next)02-24
IPO2000-06-22
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
BLU.CA short term performance overview.The bars show the price performance of BLU.CA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 50 100 150

BLU.CA long term performance overview.The bars show the price performance of BLU.CA in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of BLU.CA is 1.54 CAD. In the past month the price increased by 1.32%.

BLUENERGIES LTD / BLU Daily stock chart

BLU.CA Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to BLU.CA.


Chartmill TA Rating
Chartmill Setup Rating
BLU.CA Full Technical Analysis Report

BLU.CA Financial Highlights


Industry RankSector Rank
PM (TTM) N/A
ROA N/A
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)N/A
Revenue 1Y (TTM)N/A
BLU.CA financials

BLU.CA Forecast & Estimates


Analysts
Analysts76
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A
BLU.CA Analyst EstimatesBLU.CA Analyst Ratings

BLU.CA Ownership

Ownership
Inst OwnersN/A
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
BLU.CA Ownership

BLU.CA Competitors/Peers

The largest stocks on the Canadian markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
EPRX EUPRAXIA PHARMACEUTICALS INC N/A584.844M
EDT SPECTRAL MEDICAL INC N/A374.477M
HBP HELIX BIOPHARMA CORP N/A148.941M
MDNA MEDICENNA THERAPEUTICS CORP N/A68.396M
COV COVALON TECHNOLOGIES LTD12.9444.192M
BCT BRIACELL THERAPEUTICS CORP N/A39.15M
MBX MICROBIX BIOSYSTEMS INC5.6931.867M
RVX RESVERLOGIX CORP N/A28.756M
HEM HEMOSTEMIX INC N/A16.596M
MPH MEDICURE INC N/A11.693M

About BLU.CA

Company Profile

BLU logo image BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. The company is headquartered in Laval, Quebec and currently employs 74 full-time employees. The company went IPO on 2000-06-22. The firm's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The firm has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The firm is focused on initiating Phase III program. The firm is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.

Company Info

BLUENERGIES LTD

275 Armand-Frappier Blvd

Laval QUEBEC H7V 4A7 CA

CEO: Roberto Bellini

Employees: 74

BLU Company Website

BLU Investor Relations

Phone: 14506804500.0

BLUENERGIES LTD / BLU.CA FAQ

Can you describe the business of BLUENERGIES LTD?

BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. The company is headquartered in Laval, Quebec and currently employs 74 full-time employees. The company went IPO on 2000-06-22. The firm's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The firm has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The firm is focused on initiating Phase III program. The firm is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.


What is the stock price of BLUENERGIES LTD today?

The current stock price of BLU.CA is 1.54 CAD. The price decreased by -0.65% in the last trading session.


What is the dividend status of BLUENERGIES LTD?

BLU.CA does not pay a dividend.


What is the ChartMill technical and fundamental rating of BLU stock?

BLU.CA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 0 out of 10.


What is the market capitalization of BLU stock?

BLUENERGIES LTD (BLU.CA) has a market capitalization of 195.27M CAD. This makes BLU.CA a Micro Cap stock.